Modafinil: The U.S. experience

Michael Thorpy

Modafinil: The U.S. experience

Neurology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Clinical research in the United States on the wake-promoting agent modafinil began in 1993, when Cephalon, Inc., a Pennsylvania-based biotechnology firm, licensed the rights to modafinil in the U.S. from its developer, French pharmaceutical company Laboratorie L. Lafon (1). Modafinil was approved for use in narcolepsy in France in 1992, and had been studied in other disorders of excessive sleepiness in that country, as well as for depression and “vigilance enhancement” (1,2).

Original language	English (US)
Title of host publication	Narcolepsy and Hypersomnia
Publisher	CRC Press
Pages	571-582
Number of pages	12
ISBN (Electronic)	9781420019254
ISBN (Print)	9780849337154
State	Published - Jan 1 2006

ASJC Scopus subject areas

General Medicine

Cite this

@inbook{4ba44feb8a4e49cea437baff14ca74bb,

title = "Modafinil: The U.S. experience",

abstract = "Clinical research in the United States on the wake-promoting agent modafinil began in 1993, when Cephalon, Inc., a Pennsylvania-based biotechnology firm, licensed the rights to modafinil in the U.S. from its developer, French pharmaceutical company Laboratorie L. Lafon (1). Modafinil was approved for use in narcolepsy in France in 1992, and had been studied in other disorders of excessive sleepiness in that country, as well as for depression and “vigilance enhancement” (1,2).",

author = "Michael Thorpy",

note = "Publisher Copyright: {\textcopyright} 2007 by Taylor & Francis Group, LLC.",

year = "2006",

month = jan,

day = "1",

language = "English (US)",

isbn = "9780849337154",

pages = "571--582",

booktitle = "Narcolepsy and Hypersomnia",

publisher = "CRC Press",

}

TY - CHAP

T1 - Modafinil

T2 - The U.S. experience

AU - Thorpy, Michael

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Clinical research in the United States on the wake-promoting agent modafinil began in 1993, when Cephalon, Inc., a Pennsylvania-based biotechnology firm, licensed the rights to modafinil in the U.S. from its developer, French pharmaceutical company Laboratorie L. Lafon (1). Modafinil was approved for use in narcolepsy in France in 1992, and had been studied in other disorders of excessive sleepiness in that country, as well as for depression and “vigilance enhancement” (1,2).

AB - Clinical research in the United States on the wake-promoting agent modafinil began in 1993, when Cephalon, Inc., a Pennsylvania-based biotechnology firm, licensed the rights to modafinil in the U.S. from its developer, French pharmaceutical company Laboratorie L. Lafon (1). Modafinil was approved for use in narcolepsy in France in 1992, and had been studied in other disorders of excessive sleepiness in that country, as well as for depression and “vigilance enhancement” (1,2).

UR - http://www.scopus.com/inward/record.url?scp=85056683264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056683264&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056683264

SN - 9780849337154

SP - 571

EP - 582

BT - Narcolepsy and Hypersomnia

PB - CRC Press

ER -

Modafinil: The U.S. experience

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this